Search Results - "Chandana, S.R."

319MO Real-world monitoring of circulating tumor DNA reliably predicts cancer recurrence in patients with resected stages I-III colorectal cancer by Cohen, S.A., Kasi, P.M., Aushev, V.N., Hanna, D.L., Botta, G.P., Sharif, S., Laliotis, G., Sharma, S., Sharma, V., Alqahtani, A., Chandana, S.R., S. Kang, Chakrabarti, S., Somer, B.G., Kasi, A., Dayyani, F., Malla, M., Jurdi, A., Aleshin, A., Kopetz, S.

Get full text

525P Efficacy, safety, pharmacokinetic (PK) and pharmacodynamic (PD) data from phase I dose escalation of a novel therapeutic peptide, ST101, targeting the oncogenic transcription factor C/EBPβ, in patients (pts) with advanced and metastatic solid tumors by Mckean, M.A., Lakhani, N.J., Arkenau, H-T., Symeonides, S., Evans, T.R.J., Lim, E.A., Fontana, E., Bupathi, M., Mclaren, A., Chandana, S.R., Ding, T-E., Rotolo, J., Capiaux, G., Michel, R., Kaesshaefer, S., Bexon, A., Falchook, G.S.

Get full text

530MO Clinical benefit in biomarker-positive patients (pts) with locally advanced or metastatic solid tumours treated with the PARP1/2 inhibitor pamiparib in combination with low-dose (LD) temozolomide (TMZ) by Stradella, A., Johnson, M., Goel, S., Chandana, S.R., Galsky, M.D., Calvo, E., Moreno, V., Park, H., Arkenau, T., Cervantes, A., Fariñas-Madrid, L., Mileshkin, L., Fu, S., Plummer, R., Evans, J., Horvath, L., Prawira, A., Qu, K., Pelham, R., Barve, M.A.

Get full text

1019O Phase I studies of Sym021, an anti-PD-1 antibody, alone and in combination with Sym022 (anti-LAG-3) or Sym023 (anti-TIM-3) by Lakhani, N., Spreafico, A., Tolcher, A.W., Rodon, J., Janku, F., Chandana, S.R., Oliva, M., Sharma, M., Abdul-Karim, R.M., Hansen, U.H., Hansen, L., Skartved, N.J.Ø., Poulsen, T.T., Nadal, R.P., Lantto, J., Wood, D.L., Nadler, P.I., Siu, L.L.

Get full text

SIOG2024-1-OA-001 Randomized phase II study of Gemcitabine/Nab-Paclitaxel compared with 5-Fluorouracil/Leucovorin/Liposomal Irinotecan in older patients with treatment-naïve metastatic pancreatic cancer (GIANT EA2186) by Dotan, E., Catalano, P., Lenchik, L., Boutin, R., Yao, X., Ohr, J.P., Lim, K.-H., Vijayvergia, N., Chandana, S.R., Kalyan, A., Dunne, R.F., Zhen, D.B., Li, D., Simon, M.A., Berlin, J., Wagner, L.I., O'Dwyer, P.J.

Get full text

A phase I study of Sym021, an anti-PD-1 antibody (Ab), alone and in combination with Sym022 (anti-LAG-3) or Sym023 (anti-TIM-3) by Spreafico, A., Janku, F., Rodon, J.A., Tolcher, A.W., Chandana, S.R., Oliva, M., Musalli, S., Knauss, L., Kragh, M., Alifrangis, L., Fröhlich, C., Melander, M.C., Blondal, T., Pedersen, M.W., Lantto, J., Wood, D., Nadler, P.I., Horak, I.D., Siu, L.L., Lakhani, N.

Get full text

1197P - A phase I study of Sym021, an anti-PD-1 antibody (Ab), alone and in combination with Sym022 (anti-LAG-3) or Sym023 (anti-TIM-3) by Spreafico, A., Janku, F., Rodon, J.A., Tolcher, A.W., Chandana, S.R., Oliva, M., Musalli, S., Knauss, L., Kragh, M., Alifrangis, L., Fröhlich, C., Melander, M.C., Blondal, T., Pedersen, M.W., Lantto, J., Wood, D., Nadler, P.I., Horak, I.D., Siu, L.L., Lakhani, N.

“…Although anti-PD-(L)1 Abs are becoming standard of care for various cancers, combinations with other agents are being studied to improve the activity further…”
Get full text

451PD - Updated results of the PARP1/2 inhibitor pamiparib in combination with low-dose (ld) temozolomide (TMZ) in patients (pts) with locally advanced or metastatic solid tumours by Stradella, A., Johnson, M.L., Goel, S., Chandana, S.R., Galsky, M.D., Calvo, E., Moreno, V., Park, H., Arkenau, H.-T., Cervantes, A., Madrid, L Fariñas, Mileshkin, L., Plummer, R., Evans, J., Horvath, L., Prawira, A., Pelham, R.J., Mu, S., Andreu-Vieyra, C., Barve, M.

“…DNA damage caused by TMZ can sensitize tumors to PARP inhibitors. Pamiparib is an investigational PARP1/2 inhibitor that has shown PARP trapping activity,…”
Get full text

Updated results of the PARP1/2 inhibitor pamiparib in combination with low-dose (ld) temozolomide (TMZ) in patients (pts) with locally advanced or metastatic solid tumours by Stradella, A., Johnson, M.L., Goel, S., Chandana, S.R., Galsky, M.D., Calvo, E., Moreno, V., Park, H., Arkenau, H.-T., Cervantes, A., Madrid, L Fariñas, Mileshkin, L., Plummer, R., Evans, J., Horvath, L., Prawira, A., Pelham, R.J., Mu, S., Andreu-Vieyra, C., Barve, M.

Get full text